Please login to the form below

Not currently logged in
Email:
Password:

Vertex

This page shows the latest Vertex news and features for those working in and with pharma, biotech and healthcare.

NICE’s long-serving chief exec Sir Andrew Dillon to step down

NICE’s long-serving chief exec Sir Andrew Dillon to step down

Sir Andrew recently became personally involved in the long-running and very public dispute with Vertex over its cystic fibrosis drug Orkambi, criticising the firm for its inflexibility, but he has

Latest news

  • Vertex faces rejection of its CF medicines in Scotland Vertex faces rejection of its CF medicines in Scotland

    The SMC’s decision follows a history of rejections of Vertex’s CF drugs, with NHS England labelling the American pharma company an “extreme outlier” in its pricing and behaviour. ... The pricing disagreements are likely to continue, with Vertex

  • Leiden reassures on key role at Vertex Leiden reassures on key role at Vertex

    Under Leiden’s leadership, Vertex has gone from strength to strength since he took over the company in 2011. ... worldwide. However the high price of its treatments means Leiden and Vertex have been bedevilled by controversy, especially in Europe.

  • Who's calling the shots in European healthcare? Who's calling the shots in European healthcare?

    Natsis believes that the rules of the game are changing, pointing to the UK government’s row with Vertex over cystic fibrosis drug Orkambi as a prime example. ... He blames the situation on the ‘arrogance’ of Vertex, which he claims the rest of the

  • Vertex files cystic fibrosis triple therapy with FDA Vertex files cystic fibrosis triple therapy with FDA

    If approved, the triple therapy could transform treatment of the disease – and Vertex’s fortunes with it. ... approved Vertex medicine, as well as toward providing significantly enhanced benefits to patients with two F508del mutations.

  • FDA starts speedy review of Novartis’ sickle cell antibody FDA starts speedy review of Novartis’ sickle cell antibody

    Meanwhile, a CRISPR-based gene-editing therapy is in development at CRISPR Therapeutics and Vertex, with trials of the therapy – called CTX001 - already on the go in thalassaemia and due to

More from news
Approximately 49 fully matching, plus 78 partially matching documents found.

Latest Intelligence

  • The Cystic Fibrosis Buyers’ Club The Cystic Fibrosis Buyers’ Club

    Just Treatment is also urging the UK government to override Vertex’s patent via compulsory licensing or Crown Use Licence. ... Meticulous preparations. The supply of the generic drug comes from Argentinian pharma company Gador, whose Lucaftor is a copy

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    Its high prices are controversial, but Vertex also embodies the best of biopharma drug development. ... The failure of Proteostasis has led analysts to upgrade forecasts for Vertex’s own franchise.

  • The Orkambi row explained The Orkambi row explained

    Is Vertex’s price reasonable? This is the million dollar question, so to speak. ... October 2016: Orkambi negotiations between Vertex, the UK government and the NHS get underway.

  • The Orkambi blame game The Orkambi blame game

    an overly generous deal on Vertex’s first CF drug, Kalydeco, in 2012. ... Vertex, at £850m a year, would go out of business in three to five years.

  • #OrkambiNow? #OrkambiNow?

    Looking to the future, Vertex and other companies will be developing more potent treatments, including gene therapies which could one day cure patients of this terrible disease. ... Fast forward to July 2018, and the row had escalated to the point where

More from intelligence
Approximately 6 fully matching, plus 19 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 11 partially matching documents found.

Latest from PMHub

  • Cogora

    Reckitt Benckiser. Stallergenes. Sun Pharma. Takeda. ThermoFisher Scientific. Vertex.

  • GCI Health

    Global: Acelity,  Bayer, Janssen, Kite (a Gilead Company), Merck, MSD, Pfizer, Vertex.

  • Warehousing of HCV patients reaches new high

    New drugs from Vertex (Incivek) and Merck (Victrelis) have been welcomed because they are more effective, but they still need to be given with Interferon.

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics